8305C

8305C is a human cell line that was developed from an anaplastic thyroid carcinoma (ATC) tumor. ATC is a rare, undifferentiated, and highly aggressive form of thyroid cancer with poor differentiation and resistance to most forms of treatment. This cell line was originally derived from a thyroid tumor sample that was taken from a 67-year-old woman with ATC. 8305C cells show epithelial-like morphology with significant pleomorphism, a common feature of malignancy, and are adherent cells that grow in standard cell culture media.

8305C cells lose common thyroid features, such as iodine uptake, with dedifferentiation but retain a high proliferative and invasive potential, similar to ATC in the clinic. This cell line is used to study the molecular basis of tumor progression, metastasis, and drug and radiation resistance, including to targeted agents such as tyrosine kinase inhibitors (TKIs). It has also been used to define the signaling pathways (e.g., PI3K/AKT, MAPK) involved in the pathogenesis of ATC and its aggressive clinical course.

8305C's rapid growth rate and genetic stability have made it a widely used cell line for drug screening assays, apoptosis studies, and molecular profiling, which have led to the development of novel anticancer therapies. The 8305C cell line has also been used in radiation biology studies due to its relative radioresistance, which can provide insights into strategies to increase the efficacy of this treatment modality. Overall, 8305C continues to be an important tool in the study of thyroid cancer and has contributed to many translational and clinical advances in this deadly disease.